Precigen Announces Further Advancement of UltraCAR-T® P

/PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the...

Related Keywords

Japan , United States , Helen Sabzevari , Javier Pinilla Ibarz , Stevenm Harasym , Globaldata Epidemiology Market Size Research , Precigen Inc , European Union , Malignant Hematology Department , Nasdaq , Exchange Commission , Moffitt Cancer Center , Research Institute , Senior Member , Lymphoma Section Head , Principal Investigator , Advancing Medicine , Receptor Tyrosine Kinase Like Orphan , Sleeping Beauty , Annual Report , Globaldata Epidemiology Market Size , Human Cancer , Clin Cancer Res , Cell Biology , Human Malignancies , Front Oncol , Tyrosine Kinase , Unique Cell Surface Expression , Receptor Tyrosine Kinase , Humanb Cell Chronic Lymphocytic , Acute Lymphoblastic , Diffuse Largeb Cell Lymphoma , Small Molecule Inhibitor , Induced Apoptosis , Pre Clinical Specificity , First In Class Monoclonal Antibody Targeting , Lymphoma Myeloma Leuk , Precigen , Nc ,